Drug Stocks to Watch (ACL, JNJ, MRK, GSK)

(EMAILWIRE.COM, July 28, 2010 ) New York, NY -Alcon, Inc. (NYSE:ACL) added 1.21% to $156.11 on over 1.63 million shares. The company said late Monday that its second-quarter profit rose 15% to $670 million, or $2.21 a share, from $582 million, or $1.94 a share, in the year-ago period. On an adjusted basis, the company would have earned $2.22 a share.

To get FREE Stock newsletters, please sign up at http://www.otcblaze.com

So far, the market capitalization of the stock stands at $46.87 billion. The stock opened today at $155.62.

Johnson & Johnson (NYSE:JNJ) advanced 0.62% to $58.10 with over 16.96 million shares. Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

So far this year, the stock has fallen over 10%. The market capitalization of the stock stands at $160.24 billion. The stock has a 52-week low of $56.86.

Merck & Co., Inc. (NYSE:MRK) slid 0.26% to $35.18 on a volume of 12.68 million shares. Merck & Co., Inc. is a global health care company that delivers health solutions through its medicines, vaccines, biologic therapies, and consumer and animal products, which it markets directly and through its joint ventures.

GlaxoSmithKline plc (ADR) (NYSE:GSK) lost 1.42% to $36.22. GlaxoSmithKline plc is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

About http://www.otcblaze.com

Our goal is to make money and help you make money too. We focus on stocks trading on the OTCBB and Pinksheets. We find that the opportunities in these markets to double or triple your investment in weeks, days or even hours is much greater than in other markets. We've seen it, we've done it, and now we want to help you get in on the action too. We do, on occasion, have some picks from the big boards too!!

Disclaimer

The disclaimer is to be read and fully understood before using our site or joining our email list.

PLEASE NOTE: The OTCBlaze.com employees are not Registered as an Investment Advisor in any jurisdiction whatsoever.

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Many times we are compensated to feature companies on our site which causes a conflict of interest.

http://www.otcblaze.com
Editor
732-229-0668
info@otcblaze.com

Source: EmailWire.Com